Bridgewater Associates’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Buy
36,707
+17,777
+94% +$526K ﹤0.01% 812
2026
Q1
$571K Buy
18,930
+8,978
+90% +$290K ﹤0.01% 864
2025
Q4
$345K Buy
+9,952
New +$351K ﹤0.01% 998

Other funds holding IMCR

Bridgewater Associates's IMCR Position: Q2 2026 in Review

Bridgewater Associates increased its Immunocore (IMCR) stake by 94% in Q2 2026, buying an estimated $526K and bringing the position to 36,707 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #812.

Bridgewater Associates first reported a position in IMCR in Q4 2025 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Bridgewater Associates held 36,707 shares of Immunocore worth $1.17M as of Q2 2026.
  • Bridgewater Associates bought 17,777 Immunocore shares in Q2 2026, an estimated $526K.
  • Immunocore made up ﹤0.01% of Bridgewater Associates's portfolio in Q2 2026, its #812 holding.
  • Bridgewater Associates first reported a position in Immunocore in Q4 2025 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.